Review of the Mechanism of Action for Supartz FX in Knee Osteoarthritis

Roy D Altman, Vinod Dasa, Jun Takeuchi

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Objective: Summarize the biologic effects of Supartz FX for knee osteoarthritis (OA), the first worldwide clinically approved intra-articular (IA) hyaluronic acid (HA) product. Design: To determine the mechanism of action from preclinical and clinical studies, a literature search was conducted of Supartz FX using academic databases from 1987 to 2016. Articles on Supartz FX that deal with its mechanisms of action were extracted, categorized, and reviewed. Results: Supartz FX has 2 potential mechanisms of action: (1) biomechanical: IA Supartz FX directly improves the viscoelasticity and lubrication of synovial fluid; (2) physiologic: IA Supartz FX penetrates synovium and cartilage tissues to reach HA receptors on the surface of synoviocytes and chondrocytes. In synovium, suppression of gene expression in inflammatory mediators results in improved endogenous HA production, improved properties of synovial fluid, and reduction in pain. In cartilage, suppression of gene expression of collagenases and aggrecanases suppresses cartilage degeneration. Conclusion: The net results of basic and clinical studies is that IA Supartz FX provides a more favorable biomechanical and functional environment in the knee joint. Hence, it is not only a lubricant but is also physiologically active. These actions may help explain both short- and long-term improvement in pain and function often achieved from IA Supartz FX in knee OA.

Original languageEnglish (US)
Pages (from-to)11-20
Number of pages10
JournalCartilage
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Hyaluronic acid
Knee Osteoarthritis
Cartilage
Joints
Gene expression
Hyaluronic Acid
Synovial Membrane
Synovial Fluid
Fluids
Viscoelasticity
Lubrication
Lubricants
Gene Expression
Pain
Tissue
Collagenases
Chondrocytes
Knee Joint
Action Potentials
Databases

Keywords

  • hyaluronic acid
  • knee osteoarthritis
  • mechanism of action
  • Supartz FX

ASJC Scopus subject areas

  • Immunology and Allergy
  • Biomedical Engineering
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Review of the Mechanism of Action for Supartz FX in Knee Osteoarthritis. / Altman, Roy D; Dasa, Vinod; Takeuchi, Jun.

In: Cartilage, Vol. 9, No. 1, 01.01.2018, p. 11-20.

Research output: Contribution to journalReview article

Altman, Roy D ; Dasa, Vinod ; Takeuchi, Jun. / Review of the Mechanism of Action for Supartz FX in Knee Osteoarthritis. In: Cartilage. 2018 ; Vol. 9, No. 1. pp. 11-20.
@article{f14843e0371e466d8c01e3f5d456c23a,
title = "Review of the Mechanism of Action for Supartz FX in Knee Osteoarthritis",
abstract = "Objective: Summarize the biologic effects of Supartz FX for knee osteoarthritis (OA), the first worldwide clinically approved intra-articular (IA) hyaluronic acid (HA) product. Design: To determine the mechanism of action from preclinical and clinical studies, a literature search was conducted of Supartz FX using academic databases from 1987 to 2016. Articles on Supartz FX that deal with its mechanisms of action were extracted, categorized, and reviewed. Results: Supartz FX has 2 potential mechanisms of action: (1) biomechanical: IA Supartz FX directly improves the viscoelasticity and lubrication of synovial fluid; (2) physiologic: IA Supartz FX penetrates synovium and cartilage tissues to reach HA receptors on the surface of synoviocytes and chondrocytes. In synovium, suppression of gene expression in inflammatory mediators results in improved endogenous HA production, improved properties of synovial fluid, and reduction in pain. In cartilage, suppression of gene expression of collagenases and aggrecanases suppresses cartilage degeneration. Conclusion: The net results of basic and clinical studies is that IA Supartz FX provides a more favorable biomechanical and functional environment in the knee joint. Hence, it is not only a lubricant but is also physiologically active. These actions may help explain both short- and long-term improvement in pain and function often achieved from IA Supartz FX in knee OA.",
keywords = "hyaluronic acid, knee osteoarthritis, mechanism of action, Supartz FX",
author = "Altman, {Roy D} and Vinod Dasa and Jun Takeuchi",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/1947603516684588",
language = "English (US)",
volume = "9",
pages = "11--20",
journal = "Cartilage",
issn = "1947-6035",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Review of the Mechanism of Action for Supartz FX in Knee Osteoarthritis

AU - Altman, Roy D

AU - Dasa, Vinod

AU - Takeuchi, Jun

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: Summarize the biologic effects of Supartz FX for knee osteoarthritis (OA), the first worldwide clinically approved intra-articular (IA) hyaluronic acid (HA) product. Design: To determine the mechanism of action from preclinical and clinical studies, a literature search was conducted of Supartz FX using academic databases from 1987 to 2016. Articles on Supartz FX that deal with its mechanisms of action were extracted, categorized, and reviewed. Results: Supartz FX has 2 potential mechanisms of action: (1) biomechanical: IA Supartz FX directly improves the viscoelasticity and lubrication of synovial fluid; (2) physiologic: IA Supartz FX penetrates synovium and cartilage tissues to reach HA receptors on the surface of synoviocytes and chondrocytes. In synovium, suppression of gene expression in inflammatory mediators results in improved endogenous HA production, improved properties of synovial fluid, and reduction in pain. In cartilage, suppression of gene expression of collagenases and aggrecanases suppresses cartilage degeneration. Conclusion: The net results of basic and clinical studies is that IA Supartz FX provides a more favorable biomechanical and functional environment in the knee joint. Hence, it is not only a lubricant but is also physiologically active. These actions may help explain both short- and long-term improvement in pain and function often achieved from IA Supartz FX in knee OA.

AB - Objective: Summarize the biologic effects of Supartz FX for knee osteoarthritis (OA), the first worldwide clinically approved intra-articular (IA) hyaluronic acid (HA) product. Design: To determine the mechanism of action from preclinical and clinical studies, a literature search was conducted of Supartz FX using academic databases from 1987 to 2016. Articles on Supartz FX that deal with its mechanisms of action were extracted, categorized, and reviewed. Results: Supartz FX has 2 potential mechanisms of action: (1) biomechanical: IA Supartz FX directly improves the viscoelasticity and lubrication of synovial fluid; (2) physiologic: IA Supartz FX penetrates synovium and cartilage tissues to reach HA receptors on the surface of synoviocytes and chondrocytes. In synovium, suppression of gene expression in inflammatory mediators results in improved endogenous HA production, improved properties of synovial fluid, and reduction in pain. In cartilage, suppression of gene expression of collagenases and aggrecanases suppresses cartilage degeneration. Conclusion: The net results of basic and clinical studies is that IA Supartz FX provides a more favorable biomechanical and functional environment in the knee joint. Hence, it is not only a lubricant but is also physiologically active. These actions may help explain both short- and long-term improvement in pain and function often achieved from IA Supartz FX in knee OA.

KW - hyaluronic acid

KW - knee osteoarthritis

KW - mechanism of action

KW - Supartz FX

UR - http://www.scopus.com/inward/record.url?scp=85037612423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037612423&partnerID=8YFLogxK

U2 - 10.1177/1947603516684588

DO - 10.1177/1947603516684588

M3 - Review article

C2 - 29219021

AN - SCOPUS:85037612423

VL - 9

SP - 11

EP - 20

JO - Cartilage

JF - Cartilage

SN - 1947-6035

IS - 1

ER -